Researchers of the University of Cologne have found that autoantibodies against the cartilage protein thrombospondin 4 (TSP-4) occur in the course of arthrosis. Rheumatoid arthritis is characterized by the presence of autoantibodies, but autoantibodies against TSP-4 have jet not been described for arthrosis.
In addition to TSP-4, the researchers have found autoantibodies against the cartilage oligomeric matrix protein (COMP) and the C-type lectin domain family 3 member A (CLEC3A) in the course of OA, which may be used in a combined test together with TSP-4 in order to strengthen significance of diagnosis (Table 1).
The present invention is the first serum biomarker test that helps to support the clinical diagnosis of OA and furthermore may provide a tool that allows the monitoring of therapeutic success of drug candidates for the treatment of arthrosis.
- First biomarker of osteoarthritis
The invention is offered for licensing and further development as diagnostic test.
In case of interest we are pleased to inform you about the patent status.